Mutant HDL


Intravenous doses of a synthetic component of good cholesterol reduced artery disease
in just six weeks in a small study with startlingly big implications for treating
the nation’s No. 1 killer. (MSNBC)

I heard about this story on NPR.  The discovery and news is pretty cool, but
what struck me most was when the interviewer asked the ‘expert’ if injections of regular
HDL would have the same effect.  The expert’s answer was something like “We’ll
probably never know since the drug companies can’t patent normal HDL, and they fund
the trials.”

Comments (3)

  1. Warren says:

    I agree with comment. Like Q10 and Policosanol the drug cos aren’t interested in any "health source" that they can’t patent.